{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "PFE",
  "name": "Pfizer Inc.",
  "url": "https://frontierpicks.com/dossiers/PFE/",
  "json_url": "https://frontierpicks.com/dossiers/PFE.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Pfizer is more likely to lag the S&P 500 over the next three months because its 3 November 2026 beat-and-raise is already in the price. Its 2027 outlook, expected in mid-December 2026, settles the call: it must absorb more than $3 billion of 2027 revenue lost to patent expiries.",
  "invalidation_trigger": "A daily close above $31.50, over the 52-week intraday high of $31.44 set on 2026-11-05, which would show the shares leading again; or a 2027 outlook with adjusted EPS at or above the 2026 range of $2.95–3.05.",
  "catalyst_date": "2026-12-16",
  "catalyst_estimated": true,
  "portfolio": null,
  "pick": null,
  "themes": [
    "oncology-immunology",
    "glp1-obesity-drugs"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "PFIZER INC - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000078003/000007800326000125/pfe-9272026xex99.htm",
      "date": "2026-11-03"
    },
    {
      "title": "Finviz",
      "url": "https://finviz.com/news/414019/pfizer-reports-strong-third-quarter-2026-results-and-raises-2026-guidance",
      "date": null
    },
    {
      "title": "newsquawk.com",
      "url": "https://www.newsquawk.com/headlines/pfizer-inc-pfe-q3-2026-usd-adj-eps-087-exp-073-revenue-166bln-exp-1585bln-current-fy-eps-295-305-exp-296-current-fy-rev-62-64bln-exp-6224bln",
      "date": null
    },
    {
      "title": "Q3 2026 Earnings Conference Call Prepared Remarks",
      "url": "https://s206.q4cdn.com/795948973/files/doc_financials/2026/q3/Q3-2026-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf",
      "date": null
    },
    {
      "title": "Pfizer Aktie: Blackstone finanziert Berobenatide-Entwicklung mit bis zu 1,5 Milliarden Dollar",
      "url": "https://goldesel.de/aktien/news/pfizer-aktie-blackstone-finanziert-berobenatide-entwicklung-mit-bis-zu-15-milliarden-dollar",
      "date": null
    },
    {
      "title": "Zacks",
      "url": "https://www.zacks.com/stock/news/2805652/pfizer-issues-soft-2026-view-what-does-it-mean-for-the-stocks-future",
      "date": null
    },
    {
      "title": "pfizer.com",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-december-16",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter revenue was $16.6 billion, flat from a year earlier. Excluding Comirnaty and Paxlovid it grew 7% operationally, and launched and acquired products grew 32%.",
      "source": "Pfizer 8-K, third-quarter 2026 results release",
      "as_of": "2026-11-03"
    },
    {
      "claim": "2026 revenue guidance was raised to $62.0–64.0 billion from $60.5–62.5 billion. Adjusted EPS guidance was raised to $2.95–3.05 from $2.80–3.00.",
      "source": "Pfizer 8-K, third-quarter 2026 results release",
      "as_of": "2026-11-03"
    },
    {
      "claim": "Third-quarter adjusted EPS was $0.87, including a one-time $650 million acquired in-process research and development charge for the Innovent Biologics deal. Reported diluted EPS was $0.56.",
      "source": "Pfizer 8-K, third-quarter 2026 results release",
      "as_of": "2026-11-03"
    },
    {
      "claim": "In the third quarter, Paxlovid revenue fell 63% to $449 million, Comirnaty fell 30% to $808 million, and the Prevnar family fell 10% to $1.56 billion.",
      "source": "Pfizer 8-K, third-quarter 2026 results release",
      "as_of": "2026-11-03"
    },
    {
      "claim": "Blackstone Life Sciences will fund up to $1.5 billion of berobenatide development costs through 2028 in return for milestone payments tied to US approval and sales, with no ownership rights.",
      "source": "Pfizer and Blackstone Life Sciences announcement",
      "as_of": "2026-11-11"
    },
    {
      "claim": "Free cash flow was $11,786 million over the four quarters to 2026-09-27. Debt was $62,671 million and cash and short-term investments were $10,942 million.",
      "source": "Pfizer Form 10-Q for the third quarter of 2026",
      "as_of": "2026-11-03"
    },
    {
      "claim": "Pfizer made no share repurchases in the first nine months of 2026, with $3.3 billion of authorization remaining, and paid $1.29 a share in dividends.",
      "source": "Pfizer 8-K, third-quarter 2026 results release",
      "as_of": "2026-11-03"
    },
    {
      "claim": "Daiwa Securities moved Pfizer to Sell and raised its target to $29 from $27. DZ Bank had cut Pfizer to Hold from Buy on 2026-11-06.",
      "source": "Daiwa Securities rating change reported by fiscal.ai",
      "as_of": "2026-11-11"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-15",
    "business": "Pfizer develops, makes and sells prescription medicines and vaccines, including Eliquis, Vyndaqel, Prevnar, Padcev and Comirnaty. It sells mainly to drug wholesalers, hospitals and governments and earns money from product sales and alliance revenue. Revenue was $16,583 million in the quarter to 2026-09-27 (10-Q filed 2026-11-03).",
    "change": {
      "now": "On 2026-11-03 Pfizer raised 2026 revenue guidance to $62.0–64.0 billion and adjusted EPS guidance to $2.95–3.05. On 2026-11-11 Blackstone Life Sciences agreed to fund up to $1.5 billion of berobenatide's development.",
      "next": "Blackstone's money pays for Phase 3 obesity trials through 2028 in return for milestone payments. Pfizer plans another $2.5 billion of net savings in 2027–2029, carries $62,671 million of debt and has made no 2026 buybacks.",
      "linked": "Eli Lilly (LLY) and Novo Nordisk (NVO) face a monthly GLP-1 rival funded through Phase 3. Merck (MRK) and GSK (GSK) compete with Prevnar, down 10%, and Abrysvo. Bristol Myers Squibb (BMY) shares Eliquis."
    },
    "priced_in": "At the 2026-11-13 close (filed inputs to 2026-11-03) the shares trade at 40.8 times earnings and 3.4 times sales, with a 7.2% free-cash-flow yield and an enterprise value of $216,398 million. That holds only if free cash flow stays near the $11,786 million of the four quarters to 2026-09-27 while patent-expiry losses grow in 2027.",
    "links": {
      "customers": [
        {
          "ticker": "MCK",
          "url": "https://frontierpicks.com/dossiers/MCK/"
        },
        {
          "ticker": "COR",
          "url": null
        },
        {
          "ticker": "CAH",
          "url": null
        }
      ],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "LLY",
          "url": "https://frontierpicks.com/dossiers/LLY/"
        },
        {
          "ticker": "NVO",
          "url": "https://frontierpicks.com/dossiers/NVO/"
        },
        {
          "ticker": "MRK",
          "url": "https://frontierpicks.com/dossiers/MRK/"
        },
        {
          "ticker": "GSK",
          "url": null
        },
        {
          "ticker": "MRNA",
          "url": "https://frontierpicks.com/dossiers/MRNA/"
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-17",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-17",
      "latest_quarter": "2026-09-27",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-27",
              "filed": "2026-11-03",
              "restated": null,
              "value_musd": 16583,
              "yoy_pct": -0.4
            },
            {
              "end": "2026-06-28",
              "filed": "2026-08-04",
              "restated": null,
              "value_musd": 15034,
              "yoy_pct": 2.6
            },
            {
              "end": "2026-03-29",
              "filed": "2026-05-05",
              "restated": null,
              "value_musd": 14451,
              "yoy_pct": 5.4
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "value_musd": 17557,
              "yoy_pct": -1.2
            },
            {
              "end": "2025-09-28",
              "filed": "2025-11-04",
              "restated": null,
              "value_musd": 16654,
              "yoy_pct": -5.9
            },
            {
              "end": "2025-06-29",
              "filed": "2025-08-05",
              "restated": null,
              "value_musd": 14653,
              "yoy_pct": 10.3
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-27",
              "filed": "2026-11-03",
              "restated": null,
              "pct": 75.7
            },
            {
              "end": "2026-06-28",
              "filed": "2026-08-04",
              "restated": null,
              "pct": 72.8
            },
            {
              "end": "2026-03-29",
              "filed": "2026-05-05",
              "restated": null,
              "pct": 75.4
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "pct": 70
            },
            {
              "end": "2025-09-28",
              "filed": "2025-11-04",
              "restated": null,
              "pct": 74.9
            },
            {
              "end": "2025-06-29",
              "filed": "2025-08-05",
              "restated": null,
              "pct": 74.2
            }
          ]
        },
        "operating_margin": {
          "status": "not reported"
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "value_musd": 3385
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "four_quarters_end": "2026-09-27",
          "value_musd": 3242,
          "four_quarters_musd": 4033
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "first_end": "2025-12-31",
          "value_musd": 14173
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "first_end": "2025-12-31",
          "value_musd": 2387
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "first_end": "2025-12-31",
          "value_musd": 11786
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "base_end": "2025-09-28",
          "pct": 0.6
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "value_musd": 10942
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "value_musd": 62671,
          "composition": "non-current long-term debt plus current debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "value_musd": -51729
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2025-12-31",
          "filed": "2026-02-26",
          "value_musd": 784,
          "yoy_pct": -48.1
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "value_musd": 14192
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "value_musd": 10022
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-27",
          "filed": "2026-11-03",
          "value_musd": 89001
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-28",
          "basis_filed": "2026-11-03",
          "value_musd": 162274.8
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-28",
          "basis_filed": "2026-11-03",
          "value_musd": 214003.8
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-28",
          "basis_filed": "2026-11-03",
          "multiple": 3.4
        },
        "ev_ebit": {
          "status": "not available"
        },
        "pe": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-28",
          "basis_filed": "2026-11-03",
          "multiple": 40.2
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-28",
          "basis_filed": "2026-11-03",
          "multiple": 1.8
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-28",
          "basis_filed": "2026-11-03",
          "pct": 7.3
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 2.36,
      "days_to_cover": 4.6,
      "change_pct": -2.5
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\n\nPfizer is more likely to lag the S&P 500 over the next three months than to lead it. The third-quarter beat and the raised guidance of 2026-11-03 are already in the price. The next test is the 2027 outlook, which Pfizer is expected to give in December 2026 as it did on 2025-12-16, and that outlook has to absorb a large rise in revenue lost to patent expiries.\n\nThe quarter was strong on its own terms. Third-quarter revenue was $16.6 billion, flat from a year earlier, but revenue excluding the COVID products Comirnaty and Paxlovid grew 7% operationally and launched and acquired products grew 32% (company 8-K, 2026-11-03). Pfizer raised 2026 revenue guidance to $62.0–64.0 billion from $60.5–62.5 billion. It also raised adjusted earnings per share (EPS) guidance to $2.95–3.05 from $2.80–3.00.\n\nThe problem is the year after. In its 2026 guidance, Pfizer put revenue lost to loss of exclusivity (generic and biosimilar entry) at more than $3 billion in 2027 and more than $6 billion in 2028, as reported by Zacks after the 2025-12-16 call. The 2026 guidance carries about $1.1 billion of that kind of loss (8-K, 2026-11-03). The shares reached a 52-week intraday high of $31.44 on 2026-11-05 and closed at $28.89 on 2026-11-13. The likelier reading is that buyers are waiting for the 2027 numbers.\n\nThe rating is Low because the bar for the December outlook is high. The case for the shares leading needs 2027 guidance that holds earnings near 2026 levels despite those losses.\n\n## Bull Case\n\n- **Growth products are outrunning COVID declines.** Excluding Comirnaty and Paxlovid, third-quarter revenue grew 7% operationally, and launched and acquired products grew 32% (8-K, 2026-11-03). Padcev revenue was $720 million, up 55% from a year earlier.\n- **Guidance has been raised.** On 2026-11-03 the revenue range moved up $1.5 billion at the midpoint to $62.0–64.0 billion. Adjusted EPS guidance moved to $2.95–3.05 and includes a one-time $650 million charge for acquired in-process research and development from the Innovent Biologics deal, worth about $0.10 a share.\n- **Outside money now funds the obesity trials.** On 2026-11-11 Blackstone Life Sciences agreed to pay up to $1.5 billion of development costs for berobenatide, Pfizer's monthly GLP-1 injection, through 2028. Blackstone receives milestone payments tied to US approval and sales, and gets no ownership of the drug.\n- **The shares are cheap on cash flow.** At the 2026-11-13 close the free-cash-flow yield was 7.2%, on $11,786 million of free cash flow over the four quarters to 2026-09-27 (10-Q, 2026-11-03).\n- **More savings are planned.** Pfizer's third-quarter prepared remarks of 2026-11-03 set out another $2.5 billion of net cost savings for 2027–2029.\n\n## Bear Case\n\n- **Patent-expiry losses are about to rise.** Pfizer's 2026 guidance books about $1.1 billion of revenue lost to generics and biosimilars (8-K, 2026-11-03). Zacks reported Pfizer's projection that the loss will exceed $3 billion in 2027 and $6 billion in 2028.\n- **COVID and vaccine revenue is still falling.** In the third quarter, Paxlovid fell 63% to $449 million, Comirnaty fell 30% to $808 million, and the Prevnar pneumonia-vaccine family fell 10% to $1.56 billion (8-K, 2026-11-03).\n- **The balance sheet limits buybacks.** At 2026-09-27 Pfizer had $62,671 million of debt against $10,942 million of cash and short-term investments (10-Q, 2026-11-03). It bought back no shares in the first nine months of 2026, and its guidance assumes none for the year.\n- **Two analysts downgraded after the results.** DZ Bank cut Pfizer to Hold from Buy on 2026-11-06. Daiwa Securities moved to Sell on 2026-11-11 and raised its target to $29 from $27, which is close to the 2026-11-13 close.\n- **Lilly is ahead in obesity.** Eli Lilly won China approval for its oral GLP-1 weight-loss pill on 2026-11-12 (Benzinga). Berobenatide is only now entering Phase 3.\n\n## Setup & Price Structure\n\nThe shares closed at $28.89 on 2026-11-13. That is above the 50-day average of $28.44 and the 200-day average of $26.20, both from adjusted daily closes as of that date. The 3-month change is +9.1%.\n\nAfter the 2026-11-03 report, the shares set a 52-week intraday high of $31.44 on 2026-11-05. They closed between $28.83 and $29.45 from 2026-11-06 to 2026-11-13, through the Blackstone deal and both downgrades. The 52-week closing low is $23.67, set on 2026-06-25.\n\nThe level that matters is the 2026-11-05 high. A close back above it would show buyers paying up before the 2027 outlook. If the shares hold above the 50-day average without reaching that high, the stock is following the index while it waits for December. Measured across ten years of US stocks, there is no reliable effect so far for what happens after a sharp one-day move, a run-up or a pullback from a peak. The read here rests on the company's own results and guidance.\n\n## Catalyst Calendar\n\n- **~2026-12-16 (est.):** Full-year 2027 financial guidance call, expected to follow the 2025-12-16 precedent. This settles the call. 2027 adjusted EPS guidance at or above the 2026 range would show the business absorbing patent-expiry losses; guidance below it would confirm the lag.\n- **~2027-02-03 (est.):** Fourth-quarter and full-year 2026 results. This shows whether Comirnaty's fourth-quarter season and the growth products kept revenue inside the raised $62.0–64.0 billion range.\n\n## Elapsed catalysts\n\n- **2026-11-17:** Chief executive Albert Bourla speaks at the Jefferies London Healthcare Conference (webcast). This is the first public chance for management to frame 2027, including patent-expiry losses and the obesity program, ahead of formal guidance. *(passed)*\n\n## What Would Change Our Mind\n\nA daily close above $31.50, over the 52-week intraday high of $31.44 set on 2026-11-05, which would show the shares leading again; or a 2027 outlook with adjusted EPS at or above the 2026 range of $2.95–3.05.\n\n## Correlation Notes\n\n- **Moves with large-cap drugmakers.** Pfizer trades on the same drug-pricing and patent news as Merck (MRK), Bristol Myers Squibb (BMY) and AbbVie (ABBV). It tends to move less on news about AI or the broader economy than the S&P 500 does.\n- **Shares the Eliquis exposure with Bristol Myers Squibb.** Eliquis brought Pfizer $2.52 billion in the third quarter, up 25% (8-K, 2026-11-03). News on this blood thinner's pricing or generic entry hits both companies.\n- **Obesity news from Lilly and Novo moves the pipeline view.** Lilly's China approval of 2026-11-12 and data from Novo Nordisk (NVO) set the bar berobenatide's Phase 3 trials, funded by Blackstone since 2026-11-11, must clear.\n- **Competes with other vaccine makers.** Prevnar fell 10% and Abrysvo, the RSV vaccine, rose 9% in the third quarter (8-K, 2026-11-03). The market these products serve is contested by Merck (MRK), GSK (GSK) and Moderna (MRNA).",
  "first_seen": "2026-11-12",
  "last_analyzed": "2026-11-15T12:03:10+00:00",
  "last_synthesized": "2026-11-15",
  "date_modified": "2026-11-16",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}